Leave a request
Society’s understanding of cancer and its ability to tackle it has transformed so much over the past five decades that today, some cancers can even be described as curable, or treatable as a chronic disease
Roche has actively contributed to the transformation of the lives of people with cancer. For more than 50 years, we have developed innovative medicines and diagnostics that help prevent, detect, diagnose, treat and monitor cancer. We strive to transform the lives of people with cancer, as well as those who support them. This is our approach:
Benjamin Franklin’s quote; “An ounce of prevention is worth a pound of cure,” certainly rings true with cancer. We invest heavily into research to further our understanding of cancer and its underlying causes. With this knowledge, we helping to to raise awareness and educate healthcare professionals and people about the disease and what can be done to prevent it. For example, cervical cancer is the third most common cancer in women and a leading cause of cancer death worldwide. Through increasing awareness of the disease and our development of new diagnostic tests for the screening of human papillomavirus (HPV), its primary cause, we have contributed to improved clinical care that has made it possible to prevent cervical cancer for a vast majority of women at risk.
Treating cancer early and effectively positively impacts a patient’s quality of life, reduces the amount of time taken off work and lessens the impact that cancer has on the patient and their family. We invest heavily in disease awareness initiatives around the globe to facilitate earlier diagnosis and treatment of cancer. We have launched many cancer awareness campaigns, for example campaigns in Colombia and the USA which both focus on breast cancer.
We combine our ever-evolving knowledge of cancer biology and technological excellence with real-life clinical experience, allowing us to deliver practice-changing diagnostics that can predict and accurately diagnose the disease. In Morocco we have introduced an initiative in which we have donated HER2 tests to improve access to diagnostic tools.
Progress in cancer has been made through advances in our knowledge and understanding of the disease and its causes. Major ‘breakthroughs’ have transformed several aspects of care. Our medicines, for example, have evolved from early chemotherapy through to highly targeted monoclonal antibodies and immunotherapies. Additionally, innovative technologies such as next-generation sequencing and liquid biopsies are transforming cancer diagnostics, facilitating an evolution in personalised healthcare. These advances have changed the natural course of disease for millions of patients.
“Our expansive therapy portfolio contains 14 different cancer medicines across a number of tumour types which collectively treat well over a million people a year. The number of transformative therapies that are reaching patients is accelerating, which is really encouraging,” said Thomas Buechele, Head of Global Medical Affairs, Haematology & Oncology. “That said, despite all of the progress we have seen, around 14 million people will receive a cancer diagnosis each year. For the majority of these people, a cure for their cancer is not yet available – there is still so much work to be done.”
Our long-term vision is to prevent or cure this disease in all its forms, and our scientific rigour, industry-leading pipeline of investigational medicines and cancer immunotherapies, and our passion for progress will continue to advance cancer care in the years ahead.
Leave a request